STOCK TITAN

[Form 4] Edgewise Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Cardlytics, Inc. (CDLX) – Form 144 filing indicates an insider intends to sell 5,271 common shares on or about 02-Jul-2025 through Fidelity Brokerage on Nasdaq. The proposed sale represents ≈0.01 % of the company’s 52.5 million shares outstanding and carries an estimated market value of $9,396.

The filer—identified in the past-sales section as Nicholas Lynton—previously sold 6,057 shares in two transactions during April 2025, generating gross proceeds of $10,852. The shares to be sold were acquired via restricted-stock vesting on 01-Jul-2025 and are being disposed of for personal account purposes; no cash outlay was involved in the acquisition (classified as compensation).

Because the volume is immaterial relative to the float and no undisclosed adverse information is asserted, the filing is generally routine. Nonetheless, it signals continued insider selling within a three-month window, which investors may monitor for sentiment trends rather than fundamental impact.

Cardlytics, Inc. (CDLX) – Deposito Form 144 indica che un insider intende vendere 5.271 azioni ordinarie intorno al 02-lug-2025 tramite Fidelity Brokerage su Nasdaq. La vendita proposta rappresenta circa 0,01% delle 52,5 milioni di azioni in circolazione della società, con un valore di mercato stimato di 9.396 $.

Il dichiarante—identificato nella sezione delle vendite precedenti come Nicholas Lynton—ha già venduto 6.057 azioni in due operazioni ad aprile 2025, generando proventi lordi di 10.852 $. Le azioni da vendere sono state acquisite tramite vesting di azioni vincolate il 01-lug-2025 e vengono cedute per scopi personali; l’acquisizione non ha comportato esborso di denaro (classificata come compenso).

Poiché il volume è irrilevante rispetto al flottante e non sono segnalate informazioni negative non divulgate, il deposito è generalmente di routine. Tuttavia, segnala una continua vendita da parte degli insider in un arco di tre mesi, che gli investitori potrebbero monitorare per trend di sentiment piuttosto che per impatti fondamentali.

Cardlytics, Inc. (CDLX) – Presentación del Formulario 144 indica que un insider planea vender 5.271 acciones comunes aproximadamente el 02-jul-2025 a través de Fidelity Brokerage en Nasdaq. La venta propuesta representa aproximadamente el 0,01% de las 52,5 millones de acciones en circulación de la compañía y tiene un valor de mercado estimado de $9,396.

El declarante—identificado en la sección de ventas previas como Nicholas Lynton—vendió previamente 6.057 acciones en dos transacciones durante abril de 2025, generando ingresos brutos de $10,852. Las acciones que se venderán fueron adquiridas mediante vesting de acciones restringidas el 01-jul-2025 y se disponen para fines personales; no hubo desembolso de efectivo en la adquisición (clasificada como compensación).

Dado que el volumen es insignificante en relación con el flotante y no se afirma información adversa no divulgada, la presentación es generalmente rutinaria. Sin embargo, señala una continuación de ventas por parte de insiders en un período de tres meses, que los inversores pueden monitorear para tendencias de sentimiento más que para impacto fundamental.

Cardlytics, Inc. (CDLX) – Form 144 제출은 내부자가 2025년 7월 2일경 Fidelity Brokerage를 통해 나스닥에서 5,271 보통주를 매도할 계획임을 나타냅니다. 제안된 매도는 회사의 5,250만 주 중 약 0.01%에 해당하며, 추정 시장 가치는 9,396달러입니다.

신고자—과거 매도 내역에 니콜라스 린튼(Nicholas Lynton)으로 명시됨—는 2025년 4월 두 차례 거래에서 6,057주를 매도하여 총 10,852달러의 수익을 올렸습니다. 매도할 주식은 2025년 7월 1일 제한 주식 권리 취득(vesting)을 통해 취득되었으며 개인적 목적으로 처분되며, 취득 시 현금 지출은 없었고(보상으로 분류됨) 매도됩니다.

거래량이 유통 주식 수에 비해 미미하고 미공개 불리한 정보가 없으므로 제출은 일반적으로 일상적입니다. 그럼에도 불구하고, 이는 3개월 내 계속되는 내부자 매도를 시사하며, 투자자들은 기본적 영향보다는 심리 동향을 관찰할 수 있습니다.

Cardlytics, Inc. (CDLX) – Dépôt du Formulaire 144 indique qu’un initié prévoit de vendre 5 271 actions ordinaires aux alentours du 02-juil-2025 via Fidelity Brokerage sur le Nasdaq. La vente proposée représente environ 0,01% des 52,5 millions d’actions en circulation de la société, avec une valeur marchande estimée à 9 396 $.

Le déclarant—identifié dans la section des ventes précédentes comme Nicholas Lynton—avait déjà vendu 6 057 actions lors de deux transactions en avril 2025, générant un produit brut de 10 852 $. Les actions à vendre ont été acquises par levée de restrictions sur actions restreintes le 01-juil-2025 et sont cédées à titre personnel ; aucune dépense en espèces n’a été engagée lors de l’acquisition (classée comme rémunération).

Étant donné que le volume est négligeable par rapport au flottant et qu’aucune information défavorable non divulguée n’est signalée, le dépôt est généralement de routine. Néanmoins, il indique une poursuite des ventes d’initiés sur une période de trois mois, que les investisseurs peuvent surveiller pour des tendances de sentiment plutôt que pour un impact fondamental.

Cardlytics, Inc. (CDLX) – Form 144 Einreichung zeigt, dass ein Insider beabsichtigt, am oder um den 02.07.2025 über Fidelity Brokerage an der Nasdaq 5.271 Stammaktien zu verkaufen. Der geplante Verkauf entspricht etwa 0,01% der 52,5 Millionen ausstehenden Aktien des Unternehmens und hat einen geschätzten Marktwert von 9.396 $.

Der Einreicher—im Abschnitt zu früheren Verkäufen als Nicholas Lynton identifiziert—hat im April 2025 bereits 6.057 Aktien in zwei Transaktionen verkauft und dabei Bruttoerlöse von 10.852 $ erzielt. Die zu verkaufenden Aktien wurden am 01.07.2025 durch Restricted-Stock-Vesting erworben und werden aus persönlichen Gründen veräußert; bei der Anschaffung gab es keinen Geldausgang (als Vergütung klassifiziert).

Da das Volumen im Verhältnis zum Streubesitz unerheblich ist und keine nicht offengelegten negativen Informationen vorliegen, ist die Einreichung in der Regel routinemäßig. Dennoch signalisiert sie einen fortgesetzten Insider-Verkauf innerhalb eines Dreimonatszeitraums, den Investoren eher zur Beobachtung von Stimmungstrends als für fundamentale Auswirkungen heranziehen können.

Positive
  • None.
Negative
  • Continued insider selling within a three-month span may signal weak insider confidence, albeit at immaterial volume.

Insights

TL;DR – Minor Form 144: 5,271-share insider sale, negligible to float, modest negative sentiment only.

The notice covers an insider’s intent to sell roughly $9.4k worth of stock—less than 0.02 days of CDLX’s typical trading volume and 0.01 % of outstanding shares. The shares stem from a recent RSU vest. Two prior April sales total $10.9k, suggesting a pattern of small disposition linked to compensation events rather than a strategic exit. No operational or financial data accompany the filing; therefore, valuation or earnings outlook remain unaffected. Impact on share price should be de minimis, but persistent micro-scale insider selling can incrementally weigh on investor sentiment.

TL;DR – Routine Rule 144 filing; compliance positive, but insider sales may raise perception issues.

Timely disclosure under Rule 144 demonstrates adherence to SEC resale regulations, mitigating regulatory risk. The transaction volume is well below Rule 144 volume limits, and the seller attests to possessing no undisclosed material information, supporting governance standards. While compliance is a positive, recurring insider sales—three within one quarter—could be interpreted as lukewarm confidence, especially if unaccompanied by offsetting purchases.

Cardlytics, Inc. (CDLX) – Deposito Form 144 indica che un insider intende vendere 5.271 azioni ordinarie intorno al 02-lug-2025 tramite Fidelity Brokerage su Nasdaq. La vendita proposta rappresenta circa 0,01% delle 52,5 milioni di azioni in circolazione della società, con un valore di mercato stimato di 9.396 $.

Il dichiarante—identificato nella sezione delle vendite precedenti come Nicholas Lynton—ha già venduto 6.057 azioni in due operazioni ad aprile 2025, generando proventi lordi di 10.852 $. Le azioni da vendere sono state acquisite tramite vesting di azioni vincolate il 01-lug-2025 e vengono cedute per scopi personali; l’acquisizione non ha comportato esborso di denaro (classificata come compenso).

Poiché il volume è irrilevante rispetto al flottante e non sono segnalate informazioni negative non divulgate, il deposito è generalmente di routine. Tuttavia, segnala una continua vendita da parte degli insider in un arco di tre mesi, che gli investitori potrebbero monitorare per trend di sentiment piuttosto che per impatti fondamentali.

Cardlytics, Inc. (CDLX) – Presentación del Formulario 144 indica que un insider planea vender 5.271 acciones comunes aproximadamente el 02-jul-2025 a través de Fidelity Brokerage en Nasdaq. La venta propuesta representa aproximadamente el 0,01% de las 52,5 millones de acciones en circulación de la compañía y tiene un valor de mercado estimado de $9,396.

El declarante—identificado en la sección de ventas previas como Nicholas Lynton—vendió previamente 6.057 acciones en dos transacciones durante abril de 2025, generando ingresos brutos de $10,852. Las acciones que se venderán fueron adquiridas mediante vesting de acciones restringidas el 01-jul-2025 y se disponen para fines personales; no hubo desembolso de efectivo en la adquisición (clasificada como compensación).

Dado que el volumen es insignificante en relación con el flotante y no se afirma información adversa no divulgada, la presentación es generalmente rutinaria. Sin embargo, señala una continuación de ventas por parte de insiders en un período de tres meses, que los inversores pueden monitorear para tendencias de sentimiento más que para impacto fundamental.

Cardlytics, Inc. (CDLX) – Form 144 제출은 내부자가 2025년 7월 2일경 Fidelity Brokerage를 통해 나스닥에서 5,271 보통주를 매도할 계획임을 나타냅니다. 제안된 매도는 회사의 5,250만 주 중 약 0.01%에 해당하며, 추정 시장 가치는 9,396달러입니다.

신고자—과거 매도 내역에 니콜라스 린튼(Nicholas Lynton)으로 명시됨—는 2025년 4월 두 차례 거래에서 6,057주를 매도하여 총 10,852달러의 수익을 올렸습니다. 매도할 주식은 2025년 7월 1일 제한 주식 권리 취득(vesting)을 통해 취득되었으며 개인적 목적으로 처분되며, 취득 시 현금 지출은 없었고(보상으로 분류됨) 매도됩니다.

거래량이 유통 주식 수에 비해 미미하고 미공개 불리한 정보가 없으므로 제출은 일반적으로 일상적입니다. 그럼에도 불구하고, 이는 3개월 내 계속되는 내부자 매도를 시사하며, 투자자들은 기본적 영향보다는 심리 동향을 관찰할 수 있습니다.

Cardlytics, Inc. (CDLX) – Dépôt du Formulaire 144 indique qu’un initié prévoit de vendre 5 271 actions ordinaires aux alentours du 02-juil-2025 via Fidelity Brokerage sur le Nasdaq. La vente proposée représente environ 0,01% des 52,5 millions d’actions en circulation de la société, avec une valeur marchande estimée à 9 396 $.

Le déclarant—identifié dans la section des ventes précédentes comme Nicholas Lynton—avait déjà vendu 6 057 actions lors de deux transactions en avril 2025, générant un produit brut de 10 852 $. Les actions à vendre ont été acquises par levée de restrictions sur actions restreintes le 01-juil-2025 et sont cédées à titre personnel ; aucune dépense en espèces n’a été engagée lors de l’acquisition (classée comme rémunération).

Étant donné que le volume est négligeable par rapport au flottant et qu’aucune information défavorable non divulguée n’est signalée, le dépôt est généralement de routine. Néanmoins, il indique une poursuite des ventes d’initiés sur une période de trois mois, que les investisseurs peuvent surveiller pour des tendances de sentiment plutôt que pour un impact fondamental.

Cardlytics, Inc. (CDLX) – Form 144 Einreichung zeigt, dass ein Insider beabsichtigt, am oder um den 02.07.2025 über Fidelity Brokerage an der Nasdaq 5.271 Stammaktien zu verkaufen. Der geplante Verkauf entspricht etwa 0,01% der 52,5 Millionen ausstehenden Aktien des Unternehmens und hat einen geschätzten Marktwert von 9.396 $.

Der Einreicher—im Abschnitt zu früheren Verkäufen als Nicholas Lynton identifiziert—hat im April 2025 bereits 6.057 Aktien in zwei Transaktionen verkauft und dabei Bruttoerlöse von 10.852 $ erzielt. Die zu verkaufenden Aktien wurden am 01.07.2025 durch Restricted-Stock-Vesting erworben und werden aus persönlichen Gründen veräußert; bei der Anschaffung gab es keinen Geldausgang (als Vergütung klassifiziert).

Da das Volumen im Verhältnis zum Streubesitz unerheblich ist und keine nicht offengelegten negativen Informationen vorliegen, ist die Einreichung in der Regel routinemäßig. Dennoch signalisiert sie einen fortgesetzten Insider-Verkauf innerhalb eines Dreimonatszeitraums, den Investoren eher zur Beobachtung von Stimmungstrends als für fundamentale Auswirkungen heranziehen können.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Fox Jonathan C

(Last) (First) (Middle)
C/O EDGEWISE THERAPEUTICS, INC.
1715 38TH STREET

(Street)
BOULDER CO 80301

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/01/2025 A(1) 858 A $0.00 12,274 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Consists of restricted stock units, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. (the "Issuer") common stock, granted and released to the reporting person on July 1, 2025, as a Quarterly Retainer Award pursuant to Section 2.4 of the the Issuer's Outside Director Compensation Policy, as amended.
Remarks:
/s/ John R. Moore, Attorney-in-Fact for Fox Jonathan C 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many CDLX shares are being sold under this Form 144?

5,271 common shares are slated for sale.

What is the estimated market value of the planned CDLX share sale?

The proposed sale is valued at approximately $9,396.

When is the insider planning to sell the CDLX shares?

The approximate sale date disclosed is 02-Jul-2025.

How many CDLX shares were sold by the insider in the past three months?

Two prior transactions in April 2025 disposed of 6,057 shares in total.

What percentage of Cardlytics’ outstanding shares does the 5,271-share sale represent?

It represents about 0.01 % of the 52.5 million shares outstanding.

How were the shares being sold originally acquired?

They were received through restricted-stock vesting on 01-Jul-2025 as part of compensation.
Edgewise Therapeutics, Inc.

NASDAQ:EWTX

EWTX Rankings

EWTX Latest News

EWTX Latest SEC Filings

EWTX Stock Data

1.37B
82.28M
0.46%
111.04%
9.17%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOULDER